Antibacterial drug discovery: is small pharma the solution?

Abstract

Although antibacterial research has declined in many larger pharmaceutical companies, small companies have begun to fill in the gap. Antibacterial discovery research is currently being conducted in at least 35 small companies. One successful approach taken by small pharma has been to continue clinical programmes that were abandoned by large companies. Issues surrounding these activities, as well as proposed changes, are outlined.